Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7437052 | 0.86 | TAAR1 (0.68) | PTGS1PTGS2TAAR1AOC3MAOB | |
| SCHEMBL11288839 | 0.86 | CYP1A2 (0.68) | ACHETAAR1CYP1A2CYP2A6KMT2A | |
| SCHEMBL143961 | 0.86 | CYP1A2 (0.68) | ACHETAAR1CYP1A2CYP2A6KMT2A | |
| SCHEMBL3689463 | 0.84 | ACHE (0.68) | ACHETAAR1NFE2L2GAASMN1; SMN2 | |
| SCHEMBL7025938 | 0.83 | — | — | |
| SCHEMBL12689 | 0.83 | — | — | |
| SCHEMBL12342243 | 0.83 | TAAR1 (0.59) | ACHETAAR1CYP1A2GAALMNA | |
| SCHEMBL15079877 | 0.81 | DRD2 (0.62) | ACHECYP1A2KMT2AKCNH2MAOB | |
| SCHEMBL22894151 | 0.81 | DRD2 (0.62) | ACHECYP1A2KMT2AKCNH2MAOB | |
| SCHEMBL28577273 | 0.80 | ACHE (0.62) | ACHENFE2L2GAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7544400-B2 | Bimesogenic compounds and flexoelectric devices | MERCK PATENT GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| WO-2009032249-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK & CO., INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | ACHE 2624/4885PTGS1 3457/4885PTGS2 3168/4885 |
| US-20080142758-A1 | Bimesogenic Compounds And Flexoelectric Devices | MLX, FOXM1, SFXN1 | ACHE 4124/4885PTGS1 1014/4885PTGS2 2226/4885 |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | ACHE 1393/4885PTGS1 2274/4885PTGS2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.